Holding(s) in Company (2070T)
December 01 2011 - 11:14AM
UK Regulatory
TIDMHIK
RNS Number : 2070T
Hikma Pharmaceuticals Plc
01 December 2011
Notification of Major Interests in Shares
LONDON, 1 December 2011 - Hikma Pharmaceuticals PLC ("Hikma")
(LSE: HIK) (DIFX: HIK), the fast growing multinational
pharmaceuticals group, announces as follows:
1 Identity of the issuer or the underlying Hikma Pharmaceuticals PLC
issuer of existing shares to which the
voting rights are attached
----------------------------------------- --------------------------
2 Reason for the notification
------------------------------------------------- ----
An acquisition or disposal of voting Yes
rights
------------------------------------------------- ----
An acquisition or disposal of financial No
instruments which may result in the acquisition
of shares already issues to which voting
rights are attached
------------------------------------------------- ----
An event changing the breakdown of voting No
rights
------------------------------------------------- ----
Other (please specify): Compliance with No
the Transparency Directive
------------------------------------------------- ----
3 Full name of the person subject to the Norges Bank
notification obligation
---------------------------------------- -----------------
4 Full name of shareholders N/A
---------------------------------------- -----------------
5 Date of the Transaction (and date on 30 November 2011
which the threshold crossed is reached
differently)
---------------------------------------- -----------------
6 Date on which the issuer notified 1 December 2011
---------------------------------------- -----------------
7 Threshold that is crossed 4%
---------------------------------------- -----------------
8 Notified details (ABC)
-----------------------
A. Voting rights attached to shares
-----------------------------------------------------------------------------------------------------------
Class type Situation previous Resulting situation after the triggering
of shares to the triggering transaction
(if possible transaction
using the
ISIN code)
--------------- ------------------------ ----------------------------------------------------------------
Number Number Number of shares Number of voting % of voting
of shares of voting rights rights
rights
--------------- ----------- ----------- --------------------- --------------------- ------------------
Direct Indirect Direct Indirect Direct Indirect
--------------- ----------- ----------- ---------- --------- ---------- --------- ------- ---------
Ordinary
Shares (0.10
GBP)
GB00B0LCW083 7,656,039 7,656,039 7,971,034 0 7,971,034 0 4.08% 0%
--------------- ----------- ----------- ---------- --------- ---------- --------- ------- ---------
B. Qualifying Financial instruments
----------------------------------------------------------------------------------------------------
Resulting situation after the triggering transaction
----------------------------------------------------------------------------------------------------
Type of financial Expiration Exercise/Conversion Number of voting % of voting rights
instrument Date Period/Date rights that may
be acquired if
the instrument
if exercised/converted
------------------ ----------- -------------------- ------------------------ -------------------
- - - - -
------------------ ----------- -------------------- ------------------------ -------------------
C: Financial Instruments with similar economic effect to Qualifying
Financial Instruments
------------------------------------------------------------------------------------------------------
Resulting situation after the triggering transaction
------------------------------------------------------------------------------------------------------
Type of Exercise Expiration Exercise/Conversion Number of voting % of voting rights
financial Price Date Period/Date rights instrument
instrument refers to
------------ --------- ----------- -------------------- ------------------- ---------------------
Nominal Delta
------------ --------- ----------- -------------------- ------------------- ----------- --------
- - - - - - -
------------ --------- ----------- -------------------- ------------------- ----------- --------
Total A+B+C
---------------------------------------------
Number of Voting rights % of voting rights
------------------------ -------------------
7,971,034 4.08%
------------------------ -------------------
9 Chain of controlled undertakings through which the voting rights
and/or the financial instruments are effectively held, if applicable
----------------------------------------------------------------------
N/A
----------------------------------------------------------------------
Proxy Voting
---------------------------------------------------------
10 Name of the proxy holder Norges Bank
--- -------------------------------------- ------------
11 Number of voting rights proxy holder N/A
will cease to hold
--- -------------------------------------- ------------
12 Date on which proxy holder will cease N/A
to hold voting rights
--- -------------------------------------- ------------
13 Additional Information
--- -------------------------- ----------------------------
14 Contact name: Stanislav Boiadjiev, Norges
Bank
--- -------------------------- ----------------------------
15 Contact telephone number: +47 24 07 31 42
--- -------------------------- ----------------------------
- ENDS -
About Hikma
Hikma Pharmaceuticals PLC is a fast growing multinational group
focused on developing, manufacturing and marketing a broad range of
both branded and non-branded generic and in-licensed pharmaceutical
products. Hikma's operations are conducted through three
businesses: "Branded", "Injectables" and "Generics". Hikma's
operations are based principally in the Middle East and North
Africa ("MENA") region, where it is a market leader and sells
across 17 countries, the United States and Europe. In 2010, the
Group achieved revenues of $731 million (2009 $637 million) and
profit attributable to shareholders of $99 million (2009 $78
million).
This information is provided by RNS
The company news service from the London Stock Exchange
END
HOLUAANRAUAURAA
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jul 2023 to Jul 2024